Pfizer CEO Albert Bourla said Sunday that COVID-19 vaccine data for children ages 5 to 11 will be ready to be reviewed by the Food and Drug Administration within days.
“I think we are going to submit this data any day, so it’s a question of days, not weeks, and then it’s up to the FDA to be able to review the data and come to their conclusions,” Bourla told ABC TV’s “This Week” host George Stephanopoulos.
Bourla said the company is prepared to start producing the vaccine immediately.
The children in the trials received two doses of their specially formulated vaccine — or what amounted to about “one-fifth” of the size of the immunization given to the general population, Bourla said.
“If [government regulators] approve it, we will be ready with our manufacturing to provide this new formulation of the vaccine because the vaccine that the kids will receive … is a different formulation,” Bourla said.
Currently, only people ages 12 and older are currently able to get vaccinated with Pfizer’s vaccine.
Moderna and Johnson & Johnson’s vaccines are only approved for adults ages 18 and older.
Around 13 million children under the age of 18, or around 55 percent of 12- to 17-year-olds, have received at least one dose of a COVID-19 vaccine, according to an American Academy of Pediatrics analysis of CDC data as of Sept. 22.